Search
![SF Healthcare Week: Recursion Co-Founder & CEO Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets in development](https://static.wixstatic.com/media/08e71b_3f5fcb6937a241569bb2addbdeff0e9f~mv2.png/v1/fill/w_326,h_245,fp_0.50_0.50,q_95,enc_auto/08e71b_3f5fcb6937a241569bb2addbdeff0e9f~mv2.webp)
Jan 15
SF Healthcare Week: Recursion Co-Founder & CEO Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets in development
He discusses the merger that completed towards the end of last year, Recursion's computational and wet lab abilities, cerebral cavernous...
![Recursion's Chris Gibson on the potential utility of machine learning and AI in drug development](https://static.wixstatic.com/media/08e71b_e21353e3061540319f0b7b3df6c6b5ec~mv2.png/v1/fill/w_326,h_245,fp_0.50_0.50,q_95,enc_auto/08e71b_e21353e3061540319f0b7b3df6c6b5ec~mv2.webp)
Jan 11, 2024
Recursion's Chris Gibson on the potential utility of machine learning and AI in drug development
Chris Gibson describes the new technologies that are accelerating and refining drug development.